# US 2025/0145701 A1 · Bispecific antibody and application thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0145701 A1
- Document ID: US20250145701A1
- Status: Published application
- Kind: A1
- Application number: 18/833,897
- Filed: 2023-12-29
- Published: 2025-05-08
- Earliest claimed: 2022-12-30
- Assignees: Remegen (Shanghai) Co., Ltd.; Remegen Co., Ltd.
- Applicants: Remegen (Shanghai) Co., Ltd.; Remegen Co., Ltd.
- Inventors: Dong LI; Jianmin FANG; Mei YUAN; Shanshan CHEN; Sisi WANG; Yinghao XIN; Yuanhao LI; Guorui ZHAO; Xinting MA
- Web page: https://patentgrep.com/patent/US20250145701A1

## CPC

- C07K 16/22: against growth factors {; against growth regulators}
- A61P 35/00: Antineoplastic agents
- C07K 16/2818: {against CD28 or CD152}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/31: multispecific
- C07K 2317/522: CH1 domain
- C07K 2317/524: CH2 domain
- C07K 2317/526: CH3 domain
- C07K 2317/53: Hinge
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/567: Framework region [FR]
- C07K 2317/569: Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A VEGF-targeting VHH, a bispecific antibody targeting PD-1 and VEGF developed on the basis of the VHH, and an application thereof. The VHH has high stability, and has a plurality of excellent effects, such as ease of expression and purification. The constructed bispecific antibody targeting PD-1 and VEGF has high stability, can target enrichment in a high-expression VEGF tumor region, has good medicinal efficacy and safety, and has excellent treatment potential.

## Claims

### Claim 1

A bispecific antibody targeting programmed death receptor-1 (PD-1) and vascular endothelial growth factor (VEGF), comprising:
(a) a first binding functional region targeting PD-1; and
(b) a second binding functional region targeting VEGF;
wherein,
the first binding functional region targeting PD-1 is an anti-PD-1 antibody or an antigen-binding fragment thereof; and
the second binding functional region targeting VEGF comprises a variable domain of heavy chain of heavy-chain antibody (VHH) domain of complementarity-determining regions (CDRs) 1-3, wherein CDR1 comprises an amino acid sequence set forth in SEQ ID NO: 1, CDR2 comprises an amino acid sequence set forth in SEQ ID NO: 2 with or without one or two amino acid mutations, and CDR3 comprises an amino acid sequence set forth in SEQ ID NO: 3.

### Claim 2 (depends on 1)

The bispecific antibody according to claim 1, wherein the amino acid mutation in CDR2 is at position 58 and/or position 65.

### Claim 3 (depends on 2)

The bispecific antibody according to claim 2, wherein the amino acid mutation in CDR2 is N58Y and/or D65G mutation.

### Claim 4 (depends on 1)

The bispecific antibody according to claim 1, wherein the VHH domain is a humanized VHH domain.

### Claim 5 (depends on 1)

The bispecific antibody according to claim 1, wherein the second binding functional region targeting VEGF further comprises:
1) a first framework region domain FR1 comprising an amino acid sequence set forth in SEQ ID NO: 4 with or without one or two amino acid mutations; and/or
2) a second framework region domain FR2 comprising an amino acid sequence set forth in SEQ ID NO: 5 with or without one amino acid mutation; and/or
3) a third framework region domain FR3 comprising an amino acid sequence set forth in SEQ ID NO: 6 with or without 1-5 amino acid mutations; and/or
4) a fourth framework region domain FR4 comprising an amino acid sequence set forth in SEQ ID NO: 7 with or without one amino acid mutation;
preferably, the one or two amino acid mutations in FR1 are at position 1 and/or position 5; preferably Q1E and/or Q5L mutations;
preferably, the one amino acid mutation in FR2 is at position 49; preferably A49S mutation;
preferably, wherein the 1-5 amino acid mutations in FR3 are at positions selected from the group consisting of positions 74, 82B, 83, 84, 89, and a combination thereof;
preferably, the 1-5 amino acid mutations are selected from the group consisting of D74S, V (82B) S, K83R, P84A, M89V and a combination thereof;
preferably, the one amino acid mutation in FR4 is at position 108; preferably Q108L.

### Claim at position 6

6-9. (canceled)

### Claim 10 (depends on 5)

The bispecific antibody according to claim 5, wherein the second binding functional region targeting VEGF further comprises:
1) a first framework region domain FR1 comprising an amino acid sequence set forth in SEQ ID NO: 4 or SEQ ID NO: 9; and/or
2) a second framework region domain FR2 comprising an amino acid sequence set forth in SEQ ID NO: 5 or SEQ ID NO: 10; and/or
3) a third framework region domain FR3 comprising an amino acid sequence set forth in SEQ ID NO: 6 or SEQ ID NO: 11; and/or
4) a fourth framework region domain FR4 comprising an amino acid sequence set forth in SEQ ID NO: 7 or SEQ ID NO: 12;
preferably, the second binding functional region targeting VEGF comprises:
1) a framework region combination of FR1 comprising an amino acid sequence set forth in SEQ ID NO: 4, FR2 comprising an amino acid sequence set forth in SEQ ID NO: 5. FR3 comprising an amino acid sequence set forth in SEQ ID NO: 6, and FR4 comprising an amino acid sequence set forth in SEQ ID NO: 7; or
2) a framework region combination of FR1 comprising an amino acid sequence set forth in SEQ ID NO: 9, FR2 comprising an amino acid sequence set forth in SEQ ID NO: 10, FR3 comprising an amino acid sequence set forth in SEQ ID NO: 11, and FR4 comprising an amino acid sequence set forth in SEQ ID NO: 12; or
3) a framework region combination of FR1 comprising an amino acid sequence set forth in SEQ ID NO: 9, FR2 comprising an amino acid sequence set forth in SEQ ID NO: 5, FR3 comprising an amino acid sequence set forth in SEQ ID NO: 11, and FR4 comprising an amino acid sequence set forth in SEQ ID NO: 12.

### Claim 11

(canceled)

### Claim 12 (depends on 1)

The bispecific antibody according to claim 1, wherein the second binding functional region targeting VEGF comprises an amino acid sequence set forth in SEQ ID NO: 8 with or without 1-11 amino acid mutations;
preferably, the amino acid mutation is at a position selected from the group consisting of positions 1, 5, 49, 58, 65, 74, 82B, 83, 84, 89, 108, and a combination thereof;
preferably, the amino acid mutation is selected from the group consisting of Q1E, Q5L, A49S, N58Y, D65G, D74S, V (82B) S, K83R, P84A, M89V, Q108L and a combination thereof;
preferably, the amino acid mutation is a mutation combination of
Q1E+Q5L+A49S+N58Y+D65G+D74S+V(82B)S+K83R+P84A+M89V+Q108L; or 1)
Q1E+Q5L+N58Y+D65G+D74S+V(82B)S+K83R+P84A+M89V+Q108L. 2)

### Claim at position 10

13-15. (canceled)

### Claim 16 (depends on 1)

The bispecific antibody according to claim 1, wherein the second binding functional region targeting VEGF comprises an amino acid sequence set forth in SEQ ID NO: 8, SEQ ID NO: 13 or SEQ ID NO: 14.

### Claim 17 (depends on 1)

The bispecific antibody according to claim 1, wherein the anti-PD-1 antibody or the antigen-binding fragment thereof is selected from the group consisting of a humanized antibody or an antigen-binding fragment thereof, a chimeric antibody or an antigen-binding fragment thereof, and a human antibody or an antigen-binding fragment thereof;
preferably, the anti-PD-1 antibody or the antigen-binding fragment thereof is an IgG antibody;
preferably, the anti-PD-1 antibody or the antigen-binding fragment thereof is IgG1, IgG2, or IgG4;
preferably, the first binding functional region targeting PD-1 comprises an amino acid sequence of light chain and heavy chain CDRs identical to that of nivolumab antibody or pembrolizumab antibody;
preferably, the first binding functional region targeting PD-1 comprises an amino acid sequence of heavy chain variable region identical to nivolumab antibody or pembrolizumab antibody:
preferably, the first binding functional region targeting PD-1 comprises an amino acid sequence of light chain variable region identical to nivolumab antibody or pembrolizumab antibody;
preferably, the first binding functional region targeting PD-1 comprises a heavy chain moiety, wherein the heavy chain moiety further comprises a domain selected from the group consisting of a heavy chain constant region CH1, a hinge region, a heavy chain constant region CH2, a heavy chain constant region CH3, and a combination thereof;
preferably, the first binding functional region targeting PD-1 further comprises a light chain constant region;
preferably, the anti-PD-1 antibody comprises a heavy chain moiety and a light chain moiety, wherein the heavy chain moiety comprises, from N-terminus to C-terminus, a heavy chain variable region, a heavy chain constant region CH1, a hinge region, a heavy chain constant region CH2, and a heavy chain constant region CH3, and the light chain moiety comprises, from N-terminus to C-terminus, a light chain variable region and a light chain constant region;
preferably, the anti-PD-1 antibody comprises an Fc domain, wherein the Fc domain is an IgG1 Fc domain or a silent IgG1 mutation thereof;
preferably, the Fc domain comprises an amino acid sequence set forth in SEQ ID NO: 15 or at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to an amino acid sequence set forth in SEQ ID NO: 15;
preferably, the first binding functional region targeting PD-1 comprises a light chain and heavy chain combination of
1) a heavy chain comprising an amino acid sequence set forth in SEQ ID NO: 16, and/or a light chain comprising an amino acid sequence set forth in SEQ ID NO: 17; or
2) a heavy chain comprising an amino acid sequence set forth in SEQ ID NO: 18, and/or a light chain comprising an amino acid sequence set forth in SEQ ID NO: 19;
preferably, the second binding functional region is linked to the C-terminus or N-terminus of the first binding functional region;
preferably, the bispecific antibody is a bivalent, trivalent or tetravalent bispecific antibody; or
preferably, wherein the VHH domain is directly or via a peptide linker linked to the C-terminus or N-terminus of the heavy chain moiety of the antibody or the antigen-binding fragment thereof;
preferably, the peptide linker is a flexible peptide linker;
preferably, the peptide linker comprises one or more amino acids;
preferably, the peptide linker comprises at least 5 amino acids;
preferably, the peptide linker comprises an amino acid sequence of (GGGGS) n, wherein n is 1, 2, 3 or 4.

### Claim at position 13

18-35. (canceled)

### Claim 36 (depends on 1)

The bispecific antibody according to claim 1, wherein the bispecific antibody comprises a combination of a heavy chain set forth in SEQ ID NO: 20 and a light chain set forth in SEQ ID NO: 21, or comprises a combination of a heavy chain set forth in SEQ ID NO: 22 and a light chain set forth in SEQ ID NO: 23.

### Claim 37

A VHH domain targeting VEGF, wherein the VHH domain comprises CDRs 1-3, wherein CDR1 comprises an amino acid sequence set forth in SEQ ID NO: 1, CDR2 comprises an amino acid sequence set forth in SEQ ID NO: 2 with or without one or two amino acid mutations, and CDR3 comprises an amino acid sequence set forth in SEQ ID NO: 3.

### Claim 38 (depends on 37)

The VHH domain according to claim 37, wherein the amino acid mutation in CDR2 is at position 58 and/or position 65.

### Claim 39 (depends on 38)

The VHH domain according to claim 38, wherein the amino acid mutation in CDR2 is N58Y and/or D65G mutation;
preferably, wherein the amino acid mutation in CDR2 is N58Y and/or D65G mutation;
preferably, the VHH domain is a humanized VHH domain;
preferably, the VHH domain further comprises:
1) a first framework region domain FR1 comprising an amino acid sequence set forth in SEQ ID NO: 4 with or without one or two amino acid mutations; and/or
2) a second framework region domain FR2 comprising an amino acid sequence set forth in SEQ ID NO: 5 with or without one amino acid mutation; and/or
3) a third framework region domain FR3 comprising an amino acid sequence set forth in SEQ ID NO: 6 with or without 1-5 amino acid mutations; and/or
4) a fourth framework region domain FR4 comprising an amino acid sequence set forth in SEQ ID NO: 7 with or without one amino acid mutation;
preferably, the one or two amino acid mutations in FR1 are at position 1 and/or position 5; preferably Q1E and/or Q5L mutations; further, the one amino acid mutation in FR2 is at position 49; preferably A49S mutation;
preferably, the 1-5 amino acid mutations in FR3 are at positions selected from the group consisting of positions 74, 82B, 83, 84, 89, and a combination thereof; preferably, the 1-5 amino acid mutations are selected from the group consisting of D74S, V (82B) S, K83R, P84A, M89V and a combination thereof;
preferably, the one amino acid mutation in FR4 is at position 108; preferably Q108L;
preferably, the VHH domain further comprises:
1) a first framework region domain FR1 comprising an amino acid sequence set forth in SEQ ID NO: 4 or SEQ ID NO: 9; and/or
2) a second framework region domain FR2 comprising an amino acid sequence set forth in SEQ ID NO: 5 or SEQ ID NO: 10; and/or
3) a third framework region domain FR3 comprising an amino acid sequence set forth in SEQ ID NO: 6 or SEQ ID NO: 11; and/or
4) a fourth framework region domain FR4 comprising an amino acid sequence set forth in SEQ ID NO: 7 or SEQ ID NO: 12;
preferably, the VHH domain comprises:
1) a framework region combination of FR1 comprising an amino acid sequence set forth in SEQ ID NO: 4, FR2 comprising an amino acid sequence set forth in SEQ ID NO: 5, FR3 comprising an amino acid sequence set forth in SEQ ID NO: 6, and FR4 comprising an amino acid sequence set forth in SEQ ID NO: 7;
2) a framework region combination of FR1 comprising an amino acid sequence set forth in SEQ ID NO: 9, FR2 comprising an amino acid sequence set forth in SEQ ID NO: 10, FR3 comprising an amino acid sequence set forth in SEQ ID NO: 11, and FR4 comprising an amino acid sequence set forth in SEQ ID NO: 12; or
3) a framework region combination of FR1 comprising an amino acid sequence set forth in SEQ ID NO: 9, FR2 comprising an amino acid sequence set forth in SEQ ID NO: 5, FR3 comprising an amino acid sequence set forth in SEQ ID NO: 11, and FR4 comprising an amino acid sequence set forth in SEQ ID NO: 12.

### Claim at position 18

40-46. (canceled)

### Claim 47 (depends on 37)

The VHH domain according to claim 37, wherein the VHH domain comprises an amino acid sequence set forth in SEQ ID NO: 8 with or without 1-11 amino acid mutations;
preferably, the amino acid mutation is at a position selected from the group consisting of positions 1, 5, 49, 58, 65, 74, 82B, 83, 84, 89, 108, and a combination thereof;
preferably, the amino acid mutation is selected from the group consisting of Q1E, Q5L, A49S, N58Y, D65G, D74S, V (82B) S, K83R, P84A, M89V, Q108L and a combination thereof:
preferably, the mutation is a mutation combination of
Q1E+Q5L+A49S+N58Y+D65G+D74S+V(82B)S+K83R+P84A+M89V+Q108L; or 1)
Q1E+Q5L+N58Y+D65G+D74S+V(82B)S+K83R+P84A+M89V+Q108L; 2)
preferably, the VHH domain comprises an amino acid sequence set forth in SEQ ID NO: 8, SEQ ID NO: 13 or SEQ ID NO: 14.

### Claim at position 20

48-52. (canceled)

### Claim 53 (depends on 37)

A recombinant protein comprising the VHH domain according to claim 37;
preferably, the recombinant protein is selected from the group consisting of a bispecific antibody, a multispecific antibody, and an antibody-drug conjugate.

### Claim 54

(canceled)

### Claim 55 (depends on 1)

A polynucleotide encoding the bispecific antibody according to claim 1.

### Claim 56 (depends on 55)

An expression vector comprising the polynucleotide according to claim 55.

### Claim 57 (depends on 56)

A host cell comprising the expression vector according to claim 56.

### Claim 58 (depends on 1)

A pharmaceutical composition comprising the bispecific antibody according to claim 1, and a pharmaceutically acceptable carrier.

### Claim 59

(canceled)

### Claim 60 (depends on 1)

A method for treating cancer, comprising administering to a subject in need thereof an effective amount of the bispecific antibody according to claim 1;
preferably, the cancer is colorectal cancer.

### Claim 61

(canceled)
